WikiMD is world's largest health encyclopedia with
28,585 pages, 3,996,840 edits & 34,487,567 views.
Abagovomab
Abagovomab is a monoclonal antibody used in the treatment of ovarian cancer
Other names
- ACA 125
- Anti-idiotype ovarian cancer vaccine
- MAb ACA 125
- Monoclonal Anti-idiotype Antibody ACA125
Indications
Abagovomab is studied as an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
Mechanism of action
- A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity.
- With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation resulting in inhibition of tumor cell proliferation
Manufacturer
Abagovomab has been developed by the pharmaceutical company Menarini.
Clinical trials
A multicenter clinical trial, internationally known as MIMOSA is being studied. In this study, Abagovomab was administered as maintenance therapy after first line therapy with surgery and chemotherapy, as opposed to standard therapy with paclitaxel and carboplatin.
- Unfortunately, phase III of a trial looking at potential benefit of Abagavomab in patients treated with ovarian cancer showed no benefit in preventing a remission.
Ovarian cancer
Ovarian cancer is an aggressive type of cancer with significant mortality. In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into no longer visible residues, there is a relapse of the disease (recurrence) in more than half the women affected. In this window, after surgery and chemotherapy, ‘watch and wait’ abagovomab is potentially capable of deferring or even preventing the occurrence of the relapse.
Also see
External links
- Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
- Clinical trials
- Menarini page about abagovomab
- Clinical trial MIMOSA
WikiMD Resources - Abagovomab
Latest research (Pubmed)
Abagovomab is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever! |
---|
Medicine: Health - Encyclopedia - Topics - Diseases - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers |
Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP* |